Feedback / Questions
POZ-apomorphine (SER-252) - Serina Therap
https://www.globenewswire.com/news-release/2025/08/25/3138861/0/en/Serina-Therapeutics-Announces-FDA-Feedback-Supports-Registrational-Trial-Design-of-SER-252-in-Advanced-Parkinson-s-Disease-under-505-b-2-NDA-Pathway.html
Aug 25, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next